MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma IRVINGTON, NY--(Marketwired - May 8, 2014) - MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European...

Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET IRVINGTON, NY--(Marketwired - May 7, 2014) - MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European...

MELA Sciences Announces FDA Panel to Review MelaFind(R) PMA Application on August 26, 2010 IRVINGTON, NY--(Marketwire - May 26, 2010) -  MELA Sciences, Inc. (NASDAQ: MELA) announced today that the company's pre-market approval (PMA) application for MelaFind® will be reviewed by...